翰思艾泰港股IPO招股书失效

Group 1 - The core viewpoint of the article is that Hansai Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. has submitted its Hong Kong IPO prospectus, which has now expired after six months [1] - The company specializes in structural biology, translational medicine, and clinical development, showcasing its expertise and experience in these fields [2] - Since 2016, the company has been developing an innovative pipeline that includes one core product and nine other candidate products, focusing on oncology and autoimmune markets [2] Group 2 - The pipeline includes three clinical-stage candidates for oncology, namely the core product HX009 and major products HX301 and HX044 [2] - Additionally, there are seven preclinical candidates, which consist of antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies targeting autoimmune and oncology markets [2] - The company has previously developed HX008, which has been transferred to a biopharmaceutical company focused on oncology therapies [2]